Upload
others
View
6
Download
0
Embed Size (px)
Citation preview
SGN-SSN Interlaken | 1
Kursaal InterlakenDecember 4-6, 2013
Basics in NephrologyPflege in der NephrologieDecember 4, 2013
Schweizerische Gesellschaft für NephrologieSociété Suisse de NéphrologieSocietà Svizzera di Nefrologia
45th Annual MeetingSwiss Society of Nephrology
FinalProgram
Registration : www.meeting-com.ch
www.swissnephrology.ch
SGN-SSN Interlaken | 3
Dear ColleaguesDear Friends
Interlaken is a beautiful venue and we will certainly enjoy it, but the scientific program is the true heart of our Annual Meeting. If Interlaken will enchant you, the scientific program will satisfy your interest about nephrology today.
Historically this is an important year for nephrology and especially for dialyses in Switzer-land. Fifty years ago the first home hemodialysis on continental Europe was performed in Lauterbrunnen. Dr. Guido Bichsel from Interlaken together with Dr. Cottier played a key role for the success of this risky and courageous challenge for the time. Dr. Guido Bichsel is invited as honorary guest to this meeting. To celebrate this historic event an exhibition of old dialysis machines and devices will be shown in the exhibition area.
This year the real gem will be lectures from swiss nephrologists working in university clinics, in research and in private practice. We tried to make a balanced program with topics of general interest, general nephrology, pediatric nephrology, dialysis, transplanta-tion, hypertension, basic research and renal pathology. The highlights of the meeting will be the opening lecture, the special session on pregnancy and kidney diseases, the NCCR renal physiology lectures, and the “news and updates ” session at the end of the meeting.
Following the last year’s success, we organized again the important and interesting symposium on nursing and research in nursing, a topic getting more and more important in nephrology today. Parallel to this session will be the CME (continuous medical educa-tion), this year on renal replacement therapies. This CME will be organized by Prof. D.E. Uehlinger and the dialysis committee of our society.
The opening session will differ from last years’. This years’ opening session will include the nurses and health specialists. For this reason, a multi-language approach was chosen with French, German and English presentations. Three distinguished speakers will treat three hot topics in nephrology : salt in Switzerland, multimedia, and therapy of glomeru-lonephritis. The opening session will be closed by the poster session joined by the tradi-tional aperitif ; we hope that great discussions and networking will close this evening.
Pregnancy and nephrology is closely related. In Switzerland we have internationally recognized research on pregnancy related problems such as hypertension and preeclampsia. Together with Prof. M.G. Mohaupt, we organized a special session on pregnancy related disorders, including clinical presentations and a panel discussion to clarify important points.
Invitation 2013
Sept
embe
r 20
13
Bei ANCA-Vaskulitismit MabThera zur Remission:
Roche Pharma (Schweiz) AG
4153 Reinach www.roche-rheumatology.ch
● mindestens gleich wirksam wie CYC 1
● nach Relapse wirksamer als CYC 1
ANCA = anti-neutrophile zytoplasmatische Antikörper; CYC = Cyclophosphamid
MabThera® (Rituximab): Monoklonaler chimärer Antikörper gegen das Antigen CD20. Ind: Rheumatoide Arthritis (RA): MabThera in Kombination mit Methotrexat (MTX) ist zur Behandlung erwachsener Patienten mit mittelschwe-rer bis schwerer aktiver RA indiziert nach Versagen einer oder mehrerer Therapien mit Tumornekrosefaktor- (TNF-) Hemmern. ANCA-assoziierte Vaskulitis (AAV): MabThera in Kombination mit Kortikosteroiden ist zur Behandlung von Patienten mit schwerer aktiver AAV (Granulomatose mit Polyangiitis (auch bekannt als Morbus Wegener) und mikroskopische Polyangiitis) indiziert. D: Es soll stets eine Prämedikation verabreicht werden. RA: Ein Behandlungs-zyklus besteht aus zwei i.v. Infusionen zu je 1000 mg im Abstand von 2 Wochen. AAV: Die empfohlene Dosierung beträgt 375 mg/m2 Körperoberfl äche, einmal wöchentlich i.v. während 4 Wochen. KI: Überempfi ndlichkeit gegen Bestandteile des Arzneimittels. Aktive Infektionen. Schwere Herzinsuffi zienz (NYHA Klasse IV). In Kombination mit Methotrexat während der Schwangerschaft und Stillzeit. VM: Bei vorbestehender respiratorischer Insuffi zienz, Herzerkrankungen, Schwangerschaft, stark eingeschränkter Immunabwehr. IA: Keine IA mit MTX. UAW: Infusi-onsreaktionen, Infektionen (insbesondere der oberen Atemwege und Harnwege), Bronchospasmus/Stenoseatmung, Oedeme, Urtikaria, Alopezie, reversible Hypotonie oder Hypertonie. P: 2 Amp. MabThera zu 100 mg/10 ml und 1 Amp. zu 500 mg/50 l Infusionskonzentrat. Verkaufskategorie A. Weitere Informationen, u.a. zu onkologischen Indikationen, entnehmen Sie bitte der publizierten Fachinformation unter www.swissmedicinfo.ch. Juni 2013.
Referenz: (1) Stone JH et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New Engl J Med 2010;363:221-232.
●
●
4 | Final program SGN-SSN Interlaken | 5
Invitation 1
Organization 7
General information 8
Program at a glance 12
Program 16
Poster presentations 34
Exhibitors 44
Sponsored symposia in alphabetical order 46
City map of Interlaken 48
Dinner 49
Sponsors 50
SGN-SSN congress 2014 52
Notes 53
Table of contentsInvitation 2013
It is a privilege for the society that this year again two special NCCR lectures will be given on friday. Swiss nephrology has always been linked to excellent and internationally recognized basic research. The society is grateful to Prof. F. Verrey and Prof. J. Loffing who continue this important tradition. On behalf of the NCCR kidney.ch, they organized the main physiology session of this meeting.
In renal pathology, we are committed to follow the swiss tradition and created a new session on renal pathology with the hope that in the following years this topic will get a strong place in the annual meeting, a platform for discussion of news in renal pathology and clinical-pathological confrontations.
This year’s dinner will be in the beautiful congress venue followed by dance because we will be in the historical dance room « Ballsaal », and by that reactivate an old tradition in swiss nephrology : long time ago swiss nephrologists needed to know three to four languages for the annual meeting – and they needed to know dancing for the gala evening !
And for the first time, we introduced a “news and updates” session to close the meeting.
Join us in Interlaken for such an outstanding annual meeting of the Swiss Society on Nephrology !
Kind Regards
Prof. Dr. B. Vogt Prof. Dr. U. Huynh-DoCongress president SGN-SSN 2013 Co-congress president SGN-SSN 2013
SGN-SSN Interlaken | 7
Congress president Prof. Bruno Vogt, Inselspital, Bern
Co-congress president Prof. Uyen Huynh-Do, Inselspital, Bern
Board of the SGN-SSN President Prof. François Verrey, Zurich
President-elect Prof. Jürg Steiger, Basel
Secretary Prof. Olivier Bonny, Lausanne
Treasurer Prof. Pascal Meier, Sion
Delegates FMH and medical association Prof. Felix Brunner, Basel
Members Prof. Thomas Neuhaus, Lucerne Prof. Luca Gabutti, Lugano PD Daniel Fuster, Bern Prof. Pierre-Yves Martin, Geneva
Dialysis Committee Dr. Denes Kiss, Liestal
OrganizationUrocit.Rezidivprophylaxe des Nierensteins.1
Kaliumcitrat in WAX MATRIXKassenzulässig (BAG LIM)
Urocit® Tabletten
Z: Kalii citras 1080 mg (10 mEq), Tab- letten. I: Zur Alkalisierung des Har- nes bei Patienten mit Nierensteinen in der Anamnese, zur Rezidivpro-phylaxe. D: Im Allgemeinen ist für die Anhebung des Urin-pHs auf einen Wert von 6–7 eine Dosis von 30–60 mEq/Tag erforderlich. KI: Hyper- kaliämie, Patienten mit erhöhtem Risiko für eine Hyperkaliämie, beein- trächtigter Magendarmtransit, Ösophagus- bzw. Darmobstruktion oder -strikturen, Magen-Darm-Ulzera, aktive Harnweginfektion, einge-schränkte Nierenfunktion (GFR < 0.7 ml/kg/min), Komedikation mit kalium- sparenden Diuretika oder ACE- Hemmern. VM: Ausreichende Flüssig- keitszufuhr. Vor Therapiebeginn Elektrolyte im Serum bestimmen und Nierenfunktion kontrollieren. Bei Herzinsuffizienz oder anderen schwe- ren Myokardschädigungen möglichst nicht anwenden. Vorsicht bei Myotonia congenita. UW: Häufig gastrointestinale Störungen, welche weitgehend vermieden werden können, wenn das Präparat mit genügend Flüssigkeit eingenommen wird. IA: Kaliumsparende Diuretika, ACE-Hemmer, nicht-steroidale Anti- phlogistika, periphere Analgetika, Digitalisglykoside, Aluminiumhaltige Präparate, Präparate, die eine Verlangsamung der gastrointestina-len Transitzeit bewirken (wie z.B. Anti- cholinergika). P: Urocit 100 Tabletten. Abgabekategorie B. Kassenzuläs- sig (BAG LIM). Ausführliche Informati-onen siehe www.swissmedicinfo.ch
1. Urocit® (Kaliumcitrat): aktuelle Schweizer Fachinformation auf www.swissmedicinfo.ch
Zulassungsinhaberin:Pro Farma AG, Lindenstrasse 12 CH-6340 Baar, www.profarma.ch
06.13
ins_a5_fachpresse_urocit_d_v0613.indd 1 20.06.13 13:02
8 | Final program SGN-SSN Interlaken | 9
General information
Cancellation Written notification is required for all cancellations and changes. Cancellations of registrations should be sent to the congress secretariat. Before October 31, 2013, 50 % refund of the registration fee. Thereafter no refund.
Industrial exhibition An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee breaks will be
offered on each booth.
Hotel booking Hotel reservation possible online on www.meeting-com.ch when registering.
Congress management Meeting-com Sàrl Congress Organisation Mrs Sabine Gisler Rue des Pâquis 1, CP 100, 1033 Cheseaux-sur-Lausanne T +41 21 312 9161, F +41 21 312 9263 [email protected], www.meeting-com.ch
Abstracts The abstracts must be submitted until September 23, 2013, only via Internet on : www.swissnephrology.ch
The abstracts accepted as poster will be presented in the poster exhibition. Dimensions of posters : height 120 cm and width 90 cm.
The two highest rated posters and the highest rated oral pre-sentation on a case report will receive a poster award during the cocktail on December, 5th, 2013.
The scientific committee will select a number of abstracts which will be presented as oral presentations.
Speaking time : 8 mn and 2 mn discussion.
Confirmation Scientific contributions (oral presentations and posters) will be reviewed and confirmed by e-mail by beginning of October, 2013.
Authors presenting an accepted paper or poster must register to attend the meeting and pay the appropriate registration fee.
Congress venue Congress Centre Kursaal Interlaken Strandbadstrasse 44 3800 Interlaken
Registration & Meeting-com Sàrlcongress secretariat Rue des Pâquis 1, CP 100, CH-1033 Cheseaux-sur-Lausanne Online registration on : www.meeting-com.ch T +41 21 312 9261 – F +41 21 312 9263 – E [email protected] Onsite registration also possible (onsite fee)
Registration fee Early fee Late fee Onsite feefor congress (before Oct. 31, 2013) (Nov 1- 27, 2013) (From Nov. 28, 2013)
Member SGN-SSN CHF 180.00 CHF 220.00 CHF 250.00Non-member CHF 230.00 CHF 270.00 CHF 300.00Residents/Students* CHF 130.00 CHF 170.00 CHF 200.00
The registration fee includes : access to the scientific sessions, congress documents and lunches. The Gala Dinner is not included and has to be booked separately when registe-ring (CHF 70.00). Places are limited and a reservation is required.
*In order to benefit from the reduced fee, students or residents are required to send a document confirming their status to the SGN-SSN 2013 Congress management by fax or scanned within 7 days from the date of registration.
Registration fee Early fee Late fee Onsite feefor parallel symposia (before Oct. 31, 2013) (Nov 1- 27, 2013) (From Nov. 28, 2013)
Basics in Nephrology CHF 80.00 CHF 100.00 CHF 120.00Pflege in der Nephrologie CHF 60.00 CHF 80.00 CHF 100.00
Separate registration is required using the online-registration on www.meeting-com.
Payment Upon registration you will receive a confirmation by email together with the banking details for the payment. Payment by credit card upon registration possible.
General information
Generika in Originalqualität
10 | Final program
General information
Credits Credits points will be given by the following societies :
SGN-SSN Congress, December 4-6, 2013 SGN-SSN : 16 credit points SSGIM : 16 credit points SGAM : full length of the continuous education is creditable (1h = 1 credit) : 15.5 credit points SSGO : 2 credit points SSP : 1.5 credit points
Basics in nephrology, December 4, 2013 SGN-SSN : 3.5 credit points SGAM : full length of the continuous education is creditable (1h = 1 credit) : 4 credit points
Language Lectures in English, discussion in German, French or English. The Symposium «Pflege in der Nephrologie» will be held in
German.
Active substance: Eculizumab. Soliris (eculizumab) is indicated for the treatment of patients with atypical Haemolytic Uraemic Syndrome (aHUS). The aHUS dosing regimen for adult patients (≥18 years of age) consists of a 4-week initial phase followed by a maintenance phase:• Initial phase: 900 mg of Soliris via a 25 - 45 minute intravenous infusion every week for the first 4 weeks• Maintenance phase: 1200 mg of Soliris administered via a 25 - 45 minute intravenous infusion for the fifth week, followed by 1200 mg of Soliris administered via
a 25 - 45 minute intravenous infusion every 14 ± 2 days (see “Properties/ Effects”).
Hypersensitivity to eculizumab, murine proteins or to any of the excipients mentioned at the paragraph “composition”. Do not initiate Soliris therapy in aHUS patients:• with unresolved Neisseria meningitidis infection.• who are not currently vaccinated against Neisseria meningitidis or do not receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination
Due to its mechanism of action, Soliris increases the patient’s predisposition to meningococcal infection (Neisseria meningitidis). These patients might be at risk of disease by uncommon serogroups (particularly Y, W135 and X), although meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving Soliris. Patients less than 2 years of age and those who are treated with Soliris less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Patients must be re-vaccinated according to current medical guidelines for vaccination use. Tetravalent vaccines against serotypes A, C, Y, and W135 are strongly recommended, preferably conjugated ones.
Authorisation Holder: Alexion Pharma International Sàrl, Avenue du Tribunal-Fédéral 34 – 1005 Lausanne – Suisse Tél: +41 21 318 43 00 – Fax: +41 21 318 43 01 Authorisation Number: Swissmedic 59 282 Prescription Category: List A N
EC
/SaH
US
/13
/00
05
1. Legendre CM et al. N Engl J Med 2013;368:2169-81. 2. Licht C et al. Poster presented at 54th ASH Annual Meeting and Exposition. December 8-11, 2012; Atlanta, GA.
Chronic Soliris®
treatment improves renal function in aHUS patients1
Despite long duration of renal impairment and PE/PI, 40% (n=8/20) patients experienced a significant improvement in eGFR (≥15 mL/min/1.73m2) over 2 years.2
Secondary endpoint7 mL/min/1.73m2 mean improvement in eGFR at 2 years2
PE/PI treatment period Treatment with Soliris
-10
-5
0
5
10
15
20
Baseline (Weeks on Soliris)0 8 16 24 32 40 48 56 64 72 80 88 96 104-26 -52 -60
eGFR (estimated 3-piece trend)95% CIeGFR (simple mean)
Mea
n (S
E) C
hang
e Fr
om B
asel
ine
in e
GFR
(m
L/m
in/1
.73
m2 )
†
†Mean eGFR (SE) at baseline was 22.8±3.8 mL/min/1.73 m2. 100% of patients had eGFR <60 mL/min/1.73 m2 at baseline.1
Study C08 - 003: Patients with long duration of aHUS and chronic kidney disease (n=20).
Primary endpoint : TMA event free status
14095 aHUS Soliris A5 Ad_Swiss Soc of Nephrology.indd 1 03/09/2013 11:17
12 | Final program SGN-SSN Interlaken | 13
Program at a glanceProgram at a glance
Annual meeting of the Swiss Society of Nephrology
Time Plenary A Plenary B
16.00-16.10 Congress opening
16.10-17.20 Opening keynote lectures 1 and 2
17.20-18.00 Opening special lecture
18.00-19.00 Main poster session with aperitif at the exhibition
Satellite symposiumBasics in nephrology
Special Satellite SymposiumPflege in der Nephrologie
Time Plenary A Plenary B
10.00-10.30 Registration
10.30-11.30 Plenary sessionEröffnungForschung in der Pflege
11.30-12.00 Coffee break Kaffeepause
12.00-13.00 Plenary session Pflege und Patient
13.00-14.00 Lunch Mittagspause
14.00-15.30 Plenary session Pflege und Wissenschaft
15.30-16.00 Break – Visit of the exhibition
Wednesday, December 4, 2013 Thursday, December 5, 2013
Time Plenary A Plenary B
07.00-08.00 Registration
08.00-08.45 Keynote lecture
08.45-09.15 Special lecture
09.15-09.30 Break
09.30-10.15Satellite symposium sponsored by VIFOR
10.15-10.45 Coffee break – Visit of the exhibition – Poster viewing
10.45-11.45Oral presentationsTransplantation
Oral presentationsClinical nephrology/Hypertension
11.45-12.00 Break
12.00-12.45Satellite lunch symposium sponsored by NOVARTIS
12.45-13.45 Standing lunch
13.45-15.15 General & pediatric nephrology
15.15-15.45 Coffee break – Visit of the exhibition – Poster viewing
15.45-17.20Special symposium on pregnancy & Kidney diseases
17.20-17.30 Break
17.30-18.30 General assembly SGN-SSN
18.30-19.15 Cocktail – Poster prize awards
From 19.30 Gala dinner (Ballsaal)
SGN-SSN Interlaken | 15
Program at a glance HighVolume
HDF
«An was denken Sie bei HighVolumeHDF?»
«A quoi vous fait penser HighVolumeHDF?»
Visit us at 45th SGN-SSN Congress
2013 Interlaken.
P29250_Inserat_A5_SGN.indd 1 16.07.13 08:11
Friday December 6, 2013
Time Plenary A Plenary B
07.00-08.00 Registration
08.00-08.30 Keynote lecture
08.30-09.15 Special lecture
09.15-09.30 Break
09.30-10.15Satellite symposium sponsored by AMGEN
10.15-10.45 Coffee break – Visit of the exhibition – Poster viewing
10.45-11.45Oral presentationsDialysis
Oral presentationsNCCR/Experimental nephrology
11.45-12.00 Break
12.00-12.45Parallel satellite lunch symposia by BAXTER-GAMBRO RENAL
Parallel satellite lunch symposia by ABBVIE
12.45-13.30 Standing lunch
13.30-14.30 Parallel symposia NCCR Parallel symposia pathology
14.30-14.40 Break – Visit of the exhibition – Poster viewing
14.40-16.30 Closing Session
16.30 Farewell Address
16 | Final program SGN-SSN Interlaken | 17
Satellite CME symposium : basics in nephrologyHemodialysis : slightly beyond basicsChair:DominikUehlinger,Bern;LucaGabutti,Locarno
From 10.00 Registration
10.30-11.00 Intradialytic hypotension Georges Halabi, Yverdon
11.00-11.30 Intra- and interdialytic Hypertension Pascal Meier, Sion
11.30-12.00 Coffee break
12.00-12.30 Dialysate : optimal sodium concentration Andreas Bock, Aarau
12.30-13.00 Dialysate : optimal calcium and magnesium concentrations Stefan Farese, Solothurn
13.00-14.00 Lunch break
14.00-14.30 Sodium and ultrafiltration profiling, CritLine, BVM & Co : useful tools or fancy toys ?
Patrice Ambühl, Zürich
14.30-15.00 Dialysis water quality : does it really matter with today’s inline water filters ?
Denes Kiss, Liestal
15.00-15.30 Online Kt / V measurements : do they replace pre and postdialysis blood sampling ?
Dominik Uehlinger, Bern
15.30 End of the basics in nephrology course
15.30-16.00 Break – Visit of the exhibition
Wednesday, December 4 Room A
Special Satellite Symposium : Pflege in der NephrologieSoins en néphrologie / Nephrology nursing(Symposiumssprache : Deutsch)
Vorsitz:UrsulaDietrich,Bern;GiselaRütti,Bern
Ab 10.00 Registration
10.30-10.45 Eröffnung Bruno Vogt, Bern
10.45-11.30 Forschung in der Pflege Elisabeth Spichiger, Bern
11.30-12.00 Kaffeepause
12.00-12.30 Empfehlungen zur Erfassung der Mangelernährung bei Hämodialyse-Patientinnen und-Patienten Lea-Angelica Zürcher, Bern ; Sonja Schönberg, Bern
12.30-13.00 Informations- und Beratungsbedürfnisse von CKD I-V Patienten (ohne Ersatztherapie)
Gisela Rütti, Bern
13.00-14.00 Mittagspause
14.00-14.30 Leitfaden zur Entscheidungsfindung bei der Frage nach einem Dialyseabbruch Claudia Studer, Zürich
14.30-15.00 Aromatherapie auf der Dialysestation Silvana Tenini, Zürich
15.00-15.30 Adhärenz bei Dialysepatienten Hanna Burkhalter, Basel
15.30 Ende des Symposiums
15.30-16.00 Pause – Besuch der Ausstellung
16.00-18.00 Alle Teilnehmer sind herzlich eingeladen, an den nachfolgenden Sitzungen in Room A teilzunehmen.
Mittwoch, 4. Dezember Room B
SGN-SSN Interlaken | 19
Swiss Society of Nephrology Congress
16.00 Opening ceremony of the 45th Annual Meeting of the Swiss Society of Nephrology
16.00-16.10 Welcome address François Verrey, Zurich Bruno Vogt, Bern Uyen Huynh-Do, Bern
16.10-16.40 Opening keynote lecture 1 Chair:BrunoVogt,Bern;UyenHuynh-Do,Bern
Sel et hypertension Murielle Bochud, Lausanne
16.40-17.20 Opening keynote lecture 2 Chair:BrunoVogt,Bern;UyenHuynh-Do,Bern
Internet und Medizin Andrea Belliger, Lucerne
17.20-18.00 Opening special lecture Chair:BrunoVogt,Bern;UyenHuynh-Do,Bern
Targeting B-cells in the treatment of glomerular diseases Fernando Fervenza, Rochester (USA)
18.00-19.00 Main poster session with aperitif at the exhibition
Wednesday, December 4 Room A
This satellite symposium is sponsored by Vifor AG, Route de Moncor 10, 1752 Villars-sur-Glâne 1
45th Annual Meeting of Swiss Society of Nephrology, Interlaken, December 4–6, 2013
New perspectives for the treatment of hyperphosphatemia Prof. Dr. med. Rudolf P. Wüthrich, Universitätsspital Zürich
Optimal iron treatment in CKD: The FIND-CKD study Prof. Dr. med. Andreas Bock, Kantonsspital Aarau
Chairman: Prof. Dr. med. Rudolf P. Wüthrich
FINDing the balanceIron and phosphate management in CKD patients
Thursday, December 5, 2013, 9.30–10.15 h Room A, Kursaal Interlaken
Vif_Nephro_2013_148x210_4c_RZ.indd 1 20.09.13 16:00
20 | Final program SGN-SSN Interlaken | 21
From 07.00 Registration
08.00-08.45 Keynote lecture on transplantation Chair:JürgSteiger,Basel;ThomasFehr,Zurich
ABO incompatible renal transplantation Karine Hadaya, Geneva
Donor specific antibodies in renal transplantation Patrizia Amico, Basel
08.45-09.15 Special lecture : G. Thiel Memorial lecture Chair:JürgSteiger,Basel;ThomasFehr,Zurich
Tolerance in solid organ transplantation Déla Golshayan, Lausanne
09.15-09.30 Break
09.30-10.15 Satellite symposium Sponsored by VIFOR PHARMA :
FINDing the balance Iron and phosphate management in CKD patients Chair:RudolfP.Wüthrich,Zürich
New perspectives for the treatment of hyperphosphatemia RudolfP.Wüthrich,Zürich
Optimal iron treatment in CKD : The FIND-CKD study AndreasBock,Aarau
10.15-10.45 Coffee Break – Visit of the exhibition-poster viewing
10.45-11.45 Oral parallel presentations :
– Transplantation Room A Chair :RudolfP.Wüthrich,Zurich;DanielAckermann,Bern
– Clinical nephrology / Hypertension Room B Chair:MichaelDickenmann,Basel;PatrickSaudan,Geneva
11.45-12.00 Break
Thursday, December 5 Room A
Oral parallel presentations :
10.45-11.45 Transplantation Room A Chair :RudolfP.Wüthrich,Zurich;DanielAckermann,Bern
OC 01 Targeting apoptosis to induce tolerance across memory T cell barriers
Gabriel S.S., Chen J., Wüthrich R.P., Fehr T., Cippà P.E. – Zurich
OC 02 Potential role of T cell and platelet microvesicles in mediating anti-thymocyte-globulin-induced hypercoagulobility in transplant patients
Zecher D., Cumpelik A., Jin J., Gerossier E., Dickenmann M., Schifferli J. – Basel
OC 03 Impact of donor secretor status in ABO-incompatible living donor kidney transplantation
Drexler B.1, Holbro A.1, Sigle J.2, Gassner C.3, Schaub S.1, Amico P. 1, Infanti L.1, Stern M.1, Buser A.1, Dickenmann M.1
1 Basel, 2 Aarau, 3 Zurich
OC 04 Patient’s cooperation has a critical impact on kidney transplant waitlisting
Bruni J., Tsinalis D., Binet I. – St. Gallen
OC 05 Acute and six months mineral metabolism adaptation in living kidney donors : a prospective study
De Seigneux S., Ponte B., Trombetti A., Ernandez T., Hadaya K., Martin P.-Y. – Geneva
Oral communications
SGN-SSN Interlaken | 23
Oral communications
Oral parallel presentations :
10.45-11.45 Clinical nephrology / Hypertension Room B Chair:MichaelDickenmann,Basel;PatrickSaudan,Geneva
OC 06 Albuminuria is associated to increased phosphate level independently of GFR
De Seigneux S.M., Courbebaisse M., Wagner C., Sherrer P., Houiller P., Martin P.-Y., Feraille E. – Geneva
OC 07 Impact of proton-pump inhibitors and diuretics on the risk of hypomagnesemia in patients admitted to the emergency department
Arampatzis S.1, Lindner G.1, Funk G.-C.2, Leichtle A. B.1, Fiedler G.-M.1, Pasch A.1, Mohaupt M.1, Exadaktylos A.1
1 Berne, 2 Vienna/AT
OC 08 Serum galactose-deficient IgA1 level changes depending on the degree of immunosuppression in IgA nephropathy patients after kidney transplantation
Kim M.J.1, Schaub S.1, Molyneux K.2, Barratt J.2, Koller M.1, Jehle A.1, Steiger J.1
1 Basel, 2 Leicester/UK
OC 09 Genetically high plasma angiotensinogen potentiates L-NAME induced hypertension and promotes cardio-vascular end-organ damage in transgenic rats
Bohlender J., Gudo B. – Freiburg
OC 10 Leptin is associated with nighttime sodium excretion: a cross-sectional study in an African population
Wuerzner G.1, Maillard M.1, Bovet P.1, Teta D.1, Reyna Carmona L.E.2, Bochud M.1, Burnier M.1
1 Lausanne, 2 Seychelles/SC
AbbVie AG, Neuhofstrasse 23, CH- 6341 Baar, www.abbvie.ch
Prof. Dr. David Goldsmith, Renal and Transplantation Department, Guy’s Hospital, London Chairman: PD Dr. Andreas Pasch, Inselspital Bern
MANAGEMENT OF CKD – WHAT IS CLINICALLY RELEVANT?
INVITATION
AbbVie Lunch SymposiumFriday, December 6th, 201312.00–12.45 Room B
RZ_ABV_01_ZEM_13_005_Inserat_Lunch_Symposium_D.indd 1 25.09.13 16:46
SGN-SSN Interlaken | 25Novartis Pharma Schweiz AG, Risch I address: Suurstoffi 14, 6343 Rotkreuz, Tel. 041 763 71 11
P522
/ S
ep20
13
Confidence andConfidence and
More than 30 yearsof experience in Transplantation
Engagement
INVITATION NOVARTIS SYMPOSIUM05. December 2013 12:00 –12:45
Protection beyond rejection: Long term challenges for graft and patient in renal transplantation
Chair: Prof. J. Steiger, Basel
Engagement
Anzeige_A5.indd 1 10.09.13 11:08
12.00-12.45 Satellite lunch symposium Sponsored by NOVARTIS
Protection beyond rejection Long term challenges for graft and patient in renal transplantation
Chair:JürgSteiger,Basel
Graft protection through optimization of immunosuppressive regimens
Bruno Watschinger, Vienna (AT)
Malignancy in transplanted patient ; the potential role of mTOR inhibitors in the prevention
Günther Hofbauer, Zurich
12.45-13.45 Standing lunch at the exhibition
13.45-15.15 General and pediatric nephrology Chair:OlivierDevuyst,Zurich;ThomasNeuhaus,Lucerne
13.45-14.15 General nephrology : mechanism(s) of glomerulonephritis Uyen Huynh-Do, Bern
14.15-14.45 Pediatric nephrology Nephrotic syndrome resistant to steroids Georges Deschênes, Paris (F)
14.45-15.15 Hypertension in children Giacomo Simonetti, Bern
15.15-15.45 Coffee break – Visit of the exhibition-poster viewing
Thursday, December 5 Room A
SGN-SSN Interlaken | 27
Thursday, December 5 Room A
15.45-17.20 Special symposium on pregnancy and kidney diseases Chair:MichelBurnier,Lausanne;IsabelleBinet,St.Gallen
15.45-16.05 Preeclampsia Yvan Vial, Lausanne
16.05-16.25 Hypertension in pregnancy Antoinette Pechère, Geneva
16.25-16.45 Aldosterone in preeclampsia Markus Mohaupt, Bern
16.45-17.05 The pregnant renal patient Claudia Ferrier, Lugano
17.05-17.20 Panel discussion
17.20-17.30 Break
17.30-18.30 GENERAL ASSEMBLY SGN-SSN NeworganizationoftheSwissDialysisRegistry:PatriceAmbühl,Zurich
18.30-19.15 Cocktail
From 19.30 Gala Dinner – Poster prize awards Room B/Ballsaal
Pre-reservation is highly recommended. Price : CHF 70.00/ticket.
Congress Centre Kursaal Interlaken Strandbadstrasse 44 – 3800 Interlaken
HigH Dose HaemoDialysis symposium
Friday, December 6, 2013, 12.00-12.45
Theatersaal (Room a), Kursaal interlaken
Chairman: Prof. Dr. Dominik Uehlinger, Inselspital Bern
How do we increase
the prevalence of Home HD?
Prof. Dr. James Heaf
Herlev University Hospital, Copenhagen
Baxter AG, Müllerenstrasse 3, CH-8604 Volketswil
Transforming care together
SGN-SSN Interlaken | 29
From 07.00 Registration
08.00-08.30 Keynote lecture dialysis Chair:DenesKiss,Liestal;Pierre-YvesMartin,Geneva
High-efficiency dialyses : past, present, future ! Beat von Albertini, Lausanne
08.30-09.15 Special lecture Chair:DenesKiss,Liestal;Pierre-YvesMartin,Geneva
RAAS and hypertension Michel Burnier, Lausanne
09.15-09.30 Break
09.30-10.15 Satellite symposium Sponsored by AMGEN Chair:MichelBurnier,Lausanne
Improving the renal – cardio dialogue – what can we learn from the two specialties ?
Philip Kalra, Manchester, UK Paul Kalra, Southampton, UK
10.15-10.45 Coffee break – Visit of the exhibition-poster viewing
10.45-11.45 Oral parallel presentations : – Dialysis Room A Chair :DanielTeta,Lausanne;PascalMeier,Sion – NCCR / Experimental nephrology Room B Chair : CarstenWagner,Zürich;OlivierBonny,Lausanne
11.45-12.00 Break
Friday, December 6 Room A
45th Annual Meeting of the Swiss Society of NephrologyCongress Center Kursaal, Interlaken, December 4 – 6, 2013
invites you to a Scientifi c Symposium
Cardio – Renal Cross Talk Improving the Cardio – Renal Dialogue
What can we learn from the two specialties?
Friday December 6th, 2013 from 9.30 am to 10.15 am
Session Chair: Professor Dr Michel Burnier
CHUV Lausanne, Switzerland
Session Speakers:Professor Philip A Kalra
Salford Royal NHS Foundation Trust and University of Manchester, UK
Dr Paul R Kalra Portsmouth Hospitals NHS Trust, Portsmouth, UK
N-C
HE
-AM
G-2
34-2
013-
Jul
y-N
P
AMGEN Switzerland AG, Dammstrasse 21, 6301 Zug, www.amgen.ch
SGN_Inserat_A5_hoch.indd 1 19.07.13 10:16
30 | Final program SGN-SSN Interlaken | 31
Oral communicationsOral communications
Oral parallel presentations :
10.45-11.45 Dialysis Room A Chair :DanielTeta,Lausanne;PascalMeier,Sion
OC 11 Prevalence and predictors of sleep apnea in patients undergoing chronic intermittent hemodialysis
Forni Ogna V.1, Ogna A.1, Bassi I.1, Prujim M.1, Halabi G.2, Gauthier T.3, Bullani R.4, Phan O.5, Cherpillod A.1, Mathieu C.1, Von Albertini B.1, Teta D.1, Mihalache A.1, Burnier M.1, Heinzer R.1
1 Lausanne, 2 Yverdon, 3 Vevey, 4 Morges, 5 Payerne
OC 12 Intermittent hemodialysis reduces the severity of obstructive sleep apnea in patients with end stage renal disease by decreasing nocturnal rostral fluid shift
Ogna A.1, Forni Ogna V.1, Mihalache A.1, Halabi G.2, Prujim M.1, Cornette F.1, Rubio J.H.1, Burnier M.1, Heinzer R.1
1 Lausanne, 2 Yverdon
OC 13 Walking capacity improves survival in a large prospective swiss dialysis cohort
Winzeler R.1, Räz H.-R.2, Kiss D.3, Kistler T.4, Kneubühl A.5, Trachsler J. 5, Miozzari M.6, Ambühl P.1
1 Zurich, 2 Baden, 3 Liestal, 4 Winterthur, 5 Lachen, 6 Schauffhausen
OC 14 A multicentric prospective observational study analysing arterial stiffness in a hemodialysis cohort
Salvadé I.1, Schätti-Stählin S.1, Cereghetti C.2, Schönholzer C.3, Violetti E.3, Zwahlen H.4, Berwert L.4, Burnier M.5, Gabutti L.1
1 Locarno, 2 Mendrisio, 3 Lugano, 4 Bellinzona, 5 Lausanne
OC 15 Efficient removal of ß2-microglobulin and leptin by online hemodiafiltration : comparison of three state of the art dialyzers
Paul. B., Bock A. – Aarau
Oral parallel presentations :
10.45-11.45 NCCR / Experimental nephrology Room B Chair : CarstenWagner,Zürich;OlivierBonny,Lausanne
OC 16 The sodium/proton exchanger NHA2 is a novel regulator of sodium and calcium homeostasis in the distal convoluted tubule
Anderegg M.A., Albano G., Deisl C., Fuster D.G. – Berne
OC 17 Ureteric bud branching is suppressed by the loss of Trps1 due to the activation of TGF-ß signaling
Gui T.1, Yujing S.2, Zhibo G.2, Aiko S.2, Gengyin Z.1, Yasuteru M.2
1 Jinan/CN, 2 Kimiidera/JP
OC 18 Role of the Na/Ca exchanger NCX1 in osteoclasts : in vitro and in vivo studies
Albano G.1, Mercier Zuber A.2, Siegrist M.1, Dolder S.1, Stoudmann C.2, Hofstetter W.1, Bonny O.2, Fuster D.G.1
1 Berne, 2 Lausanne
OC 19 The renal and systemic response to an acute phosphate load : evidence against the existence of a gut-derived regulatory mechanism in humans
Scanni R., Von Rotz M., Krapf R.
OC 20 Calciprotein particles induce an inflammatory response in macrophages
Chandak P. G., Bijarnia R.K., Pasch A. – Berne
32 | Final program SGN-SSN Interlaken | 33
12.00-12.45 Parallel satellite lunch symposia
Sponsored by BAXTER-GAMBRO RENAL Room A Chair:DominikUehlinger,Bern
High Dose Haemodialysis How do we increase
the prevalence of Home HD ? James Heaf, Copenhagen, DK
Sponsored by ABBVIE Room B Chair:AndreasPasch,Bern
Management of CKD- What is Clinically relevant ? David Goldsmith, London, UK
12.45-13.30 Standing lunch at the exhibition
13.30-14.30 Parallel symposium NCCR Room A Chair:JohannesLoffing,Zurich;EricFéraille,Genève
13.30-14.00 Physiology and pathophysiology of K+ homeostasis Jens Leipziger, Aarhus (DK)
14.00-14.30 A difficult task-the control of adrenal aldosterone secretion Richard Warth, Regensburg (D)
13.30-14.30 Parallel symposium pathology Room B Chair:SolangeMoll,Geneva
14.30-14.40 Break
Friday, December 6
Room A14.40-16.30 Closing session
Chair:FrançoisVerrey,Zurich;BrunoVogt,Bern
14.40-14.50 SGN-SSN Publication Award 2013 presentation and short address
Astrid Starke and Alf Corsenca, Zurich
Updates in Nephrology
14.50-15.10 Physiology Daniel Fuster, Bern
15.10-15.30 General nephrology Sophie de Seigneux, Geneva
15.30-15.50 Hemodialysis Stephan Segerer, Zurich
15.50-16.10 Peritoneal dialysis Isabelle Binet, St. Gallen
16.10-16.30 Kidney transplantation Stefan Schaub, Basel
16.30 Farewell address Bruno Vogt, Bern François Verrey, Zurich
Friday, December 6
34 | Final program SGN-SSN Interlaken | 35
Poster presentations
P 07 Urinary stone disease after kidney transplantation : how we manage it
Keller E.-X., Mohebbi N., Müller A., Fehr T. – Zurich
P 08 Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation
Hirt-Minkowski P.1, Marti H.-P.2, Hönger G.1, Grandgirard D.3, Leib S. L.3, 4, Amico P.1, Schaub S.1
1 Basel, 2 Bergen/NO, 3 Berne, 4 Spiez
Clinical nephrology, hypertension and case reports
P 09 Recurrent bone fractures due to tenofovir induced renal phosphate wasting
Koenig K.F.1, Kalbermatter S.1, Menter T.2, Graber P.1, Kiss D.1
1 Liestal, 2 Basel
P 10 Lithium poisoning at normal serum levels in a 70-year-old patient with acute kidney failure
Hennemann J., Kneubühl A., Bregenzer T. – Lachen
P 11 Mycobacterium Haemophilum – cutaneous and pulmonary manifestation in a renal transplanted patient – diagnosis and treatment
Anghel C.1, Kamarachev J.2, Aerne D.3, Bregenzer T.1, Kneubühl A.1
1 Lachen, 2 Zurich, 3 Tuggen
P 12 Digital necrosis and renal failure Kalbermatter S.1, Menter T.2, Hopfer H.2, Kiss D.1
1 Liestal, 2 Basel
P 13 First Switzerland confirmed case of acute kidney injury associated with metamizol sodium therapy
Hemett O. M., Descombes E. – Freiburg
Transplantation
P 01 Generation of angiotensin-receptor and anti-perlecan antibodies : allo- or autoimmunity ?
Hönger G.1, Cardinal H.2, Dieudé M.2, Buser A.1, Hösli I.1, Dragun D.3, Hébert M.-J.2, Schaub S.1
1 Basel, 2 Montréal/CA, 3 Berlin/DE
P 02 Socioeconomic effects of kidney transplantation Eppenberger L., Dickenmann M. – Basel
P 03 Prevalence, etiology, therapy and implications of anemia after kidney transplantation (PTA) in a large prospective swiss transplant cohort
Winzeler R.1, Neusser M.A.1, Dickenmann M.2, Kruse A.3, Hadaya K.4, Golshayan D.5, Wüthrich R.P.1, Ambühl P.1
1 Zurich, 2 Basel, 3 Berne, 4 Geneva, 5 Lausanne
P 04 Serum CXCL10 chemokine and correlation with subclinical vascular rejection
Hirt-Minkowski P.1, Ho J.2, Gao A.2, Amico P.1, Hofper H.1, Nickerson P.1,2, Schaub S.1
1 Basel, 2 Manitoba/CA
P 05 Excellent allograft survival (and improvement of lung function parameters) in patients receiving kidney after lung transplantation
Schleich A., Heeringa S., Benden C., Brockmann J., Rüsli B., Fehr T., Schuurmans M.
P 06 Late antibody-mediated rejection and transplant glomerulopathy : how to avoid chronic rejection ?
Ferrari-Lacraz S., Bouatou Y., Ponte B., Moll S., Martin P.-Y., Villard J., Hadaya K. – Geneva
Poster presentations
36 | Final program SGN-SSN Interlaken | 37
Poster presentationsPoster presentations
P 22 Polyomavirus nephropathy caused by JCV in renal allograft recipients
De Marchi S.1, Zuliani E.1, Cereghetti C.2, Gaspert A.3, Fehr T.3, Chönholzer C.1
1 Lugano, 2 Mendrisio, 3 Zurich
P 23 A new mutation in CLCN5 causing Dent’s disease and its clinical expression
Buchkremer F., Röthlisberger B., Bock A. – Aarau
P 24 Anti-GBM disease and the nephrotic syndrome Grosse P., Klima T., Bernarsconi L., Yurtsever H., Bock A. – Aarau
P 25 Osteoanabolic treatment for severe renal osteopathy after combined kidney-liver transplantation : a case report
Arampatzis S., Bertke P., Pasch A., Huynh-Do U. – Berne
P 26 Prevalence and risk factors for chronic kidney disease in a rural region of Haiti
Burkhalter F.1, Sannon H.2, Mayr M.1, Dickenmann M.1, Ernst S.2
1 Basel, 2 Haiti/HT
P 27 Undergoing a renal biospy : how bad is it ? Matheis E., Tsinalis D., Binet I. – St. Gallen
P 28 Urinary uromodulin as a marker of renal function and mass : data from a population-based study
Pruijm M.1, Burnier M.1, Ponte B.2, Ackermann D.3, Paccaud F.1, Guessous I.1, 2, Ehret G.2, Vogt B.3, Mohaupt M.3, Martin P.-Y.2, Devuyst O.4, Bochud M.1
1 Lausanne, 2 Geneva, 3 Berne, 4 Zurich
P 14 It’s not always diabetic nephropathy Grendelmeier I.1, Hopfer H.2, Kiss D.1
1 Liestal, 2 Basel
P 15 Renal failure associated with ureaplasma urealyticum ureteritis Wallner J., Tozakidou M., Hopfer H., Jehle A.W. – Basel
P 16 Allele-specific human leukocyte antigen alloantibody causing unexpected AMR after kidney graft transplantation
Wehmeier C., Amico P., Hönger G., Schaub S. – Basel
P 17 Successful treatment of a pacemaker infection with intraperitoneal daptomycin dosed according to systemic serum drug concentrations
Kononowa N., Taegtmeyer A.,Burkhalter F. – Basel
P 18 C3 rapidly progressive glomerulonephritis as aHUS/CD46 mutation recurrence : graft loss 5 years after renal transplantation
Bouatou Y.1, Fremeaux-Bacchi V.2, Villard J.1, Moll S.1, Martin P.-Y.1, Hadaya K.1
1 Geneva, 2 Paris/FR
P 19 PEG Interferon-Alfa 2A causing minimal change disease in a patient on hepatitis C therapy
Shailesh K., Jason C.P.E – Singapore/SG
P 20 First simultaneous liver-kidney transplantation for atypical hemolytic uremic syndrome due to a factor H double mutation
Mohebbi N., Schanz U., Schadde E., Spartà G., Bonani M., Dutkowski P., Müllhaupt B., Wüthrich R.P., Fehr T. – Zurich
P 21 Eosinophilia in a Kidney Transplant Recipient with Allograft Failure Hübel K.1, Berwert L.2, Brockmann J.1, Zwahlen H.2, Mohebbi N.1,
Fehr T.1, Gaspert A.1
1 Zurich, 2 Bellinzona
38 | Final program SGN-SSN Interlaken | 39
Poster presentationsPoster presentations
P 36 Severe signs of dilutional hyponatremia secondary to desmopressin treatment for nocturnal enuresis : a systematic review of the literature
Lucchini B., Simonetti G.D., Ceschi A., Lava S.A.G., Bianchetti M.G.
P 37 Metabolic disturbances and renal stone promotion on treatment with topiramate : a systematic review of the literature
Dell’Orto V.G., Belotti E.A., Goeggel-Simonetti B., Simonetti G.D., Ramelli G.P., Bianchetti M.G., Lava S.A.G
P 38 Contrast-enhanced ultrasound in the diagnosis of acute pyelonephritis – an interim-analysis
Buchkremer F.1, Albrich W.2, Drozdov D.1, Müller B.1, Bock A.1
1 Aarau, 2 St. Gallen
P 39 Continuous subcutaneous magnesium infusion by portable pump for severe congenital hypomag- nesaemia
Bock A., Roth S. – Aarau
P 40 Serum calcification propensity predicts all-cause mortality in chronic kidney disease stages 3 & 4
Pasch A.1, Farese S.2, Holt S.3, Smith E.R.3
1 Berne, 2 Solothurn, 3 Victoria/AU
P 41 Association of ambulatory blood pressure with 17α-hydroxylase activity in the general population
Ackermann D.1, Pruijm M.2, Ponte B.3, Dick B.1, Al-Ahwan H.2, Vuistiner P.2, Guessous I.2, Ehret G.3, Paccaud F.2, Burnier M.2, Martin P.-Y.3, Vogt B.1, Mohaupt M.1, Bochud M.2
1 Berne, 2 Lausanne, 3 Geneva
P 42 Local aldosterone production in Human Umbilical Vein Endothelial Cells (HUVEC)
Jain K., Eisele N., Escher G., Gennari-Moser C., Baumann M., Albrecht C. Mohaupt M. – Berne
P 29 Caffeine levels are inversely associated with kalemia in women : a population based Study
Alwan H.1, Pruijm M.1, Ackermann D.3, Guessous I.1, 2, Ehret G.2, Vuistiner P.1, Paccaud F.1, Pechère- Bertschi A.2, Mohaupt M.3, Vogt B.3, Martin P.-Y.2, Burnier M.1, Ansermot N.1, Eap C. B.1, Bochud M.1, Ponte B.2
1 Lausanne, 2 Geneva, 3 Berne
P 30 Parathyroid hormone, hyperparathyroidism and chronic kidney disease in primary care
Tomonaga Y.1, Szucs T.D.2, Risch L.3, Ambühl M.1
1 Zurich, 2 Basel, 3 Schaan
P 31 Copeptin is associated with the presence of cysts and renal function in the general population
Ponte B.1, Pruijm M.2, Ackermann D.3, Guessous I.1, 2, Ehret G.1, Vuistiner P.2, Alwan H.2, Paccaud F.2, Pechere-Bertschi A.1, Mohaupt M.3, Vogt B.3, Burnier M.2, Devuyst O.4, Martin P.-Y.1, Bochud M.2
1 Geneva, 2 Lausanne, 3 Berne, 4 Zurich
P 32 Community- acquired acute kidney injury : a prospective observational study
De la Fuente V., Stucker F., Alves C., Carballo S., Ponte B., Vuilleumier N., Rutschmann O., Martin P.- Y., Saudan P.
P 33 Microhematuria in ADPKD Krauer F., Serra A. L., Kistler A., von Eckardstein A., Wüthrich R.P.,
Poster D. – Zurich
P 34 Hyponatremia, hypokalemia, hypochloremia or metabolic alkalosis in cystic fibrosis : systematic review of the literature
Scurati-Manzoni E., Lava S.A.G., Simonetti G.D, Zanolari-Calderari M., Bianchetti M.G.
P 35 Hyperchloremic metabolic acidosis induced by the iron chelator deferasirox (Exjade®) : a case report and review of the literature
Dell’Orto V.G., Brazzola P., Lava S.A.G., Bianchetti M.G.
40 | Final program SGN-SSN Interlaken | 41
Poster presentationsPoster presentations
P 49 Cinacalcet based management of secondary hyperparathyroidism in Swiss hemodialysis patients : 12 months data of the TRANSIT observational study
Bock A.1, Meier P.2, Tsinalis D.3
1 Aarau, 2 Sion-Hérens-Conthey, 3 St. Gallen
Experimental nephrology
P50 Sodium thiosulfate may prevent vascular calcifications via its metabolite H2S
Aghagolzadeh P., Bachtler M., Kumar B.R., Pasch A. – Berne
P 51 Effect of PA21, a new iron-based phosphate binder on FGF23 and vascular calcifications in uremic rats
Phan O., Maillard M.P., Funk F. W., Bonny O., Burnier M. – Lausanne
P 52 Beta-oxidation affects the susceptibility of podocytes to palmitic acid : critical role of acetyl-CoA carboxylase 1 and 2
Kampe K.1, Sieber J.1, 2, Orellana J.1, Mundel P.2, Jehle A.W.1
1 Basel, 2 Boston/US
P 53 Sodium thiosulfate prevents the formation of mineral matrix vesicles in uremic rats
Bijarnia R.K., Niklaus M., Chandak P.G., Pasch A. – Berne
P 54 Modern MicroCT : analysis of whole mouse kidney down to capillary level
Hlushchuk R., Correa Shokiche C., Schaad L., Wnuk M., Zubler C., Barré S., Tschanz S., Djonov V.
P 55 Physiological role of the mediator of ErbB2 induced cell motility (Memo) in mice
Moor M.B.1, Hänzi B.2, Hynes N.E.2, Bonny O.1
1 Lausanne, 2 Basel
P 43 Another unexpected role of aldosterone in pregnancy : placental angiogenesis via PlGF induction
Eisele N., Jain K., Gennari-Moser C., Escher G., Albrecht C., Baumann M., Surbek D., Mohaupt M. – Berne
P 44 Normotensive blood pressure in pregnancy – the role of salt and aldosterone
Gennari-Moser C., Escher G., Kramer S., Dick B., Eisele N., Baumann M., Raio L., Frey F. J., Surbek D., Mohaupt M. – Berne
Dialysis
P 45 Outcome of dialysis patients above and below seventy years of age – a retrospective matched-pair analysis
Scholl L.F., Dickenmann M., Hirt-Minkowski P. – Basel
P 46 Comparison of two different cholecalciferol supplements (multivitamin tablets versus oil-based droplets) in patients on long-term hemodialysis (HD)
Descombes E., Fellay B., Hemett O. M., Magnin J.-L., Fellay G. – Freiburg
P 47 Large variations in pulse wave velocity and reflection patterns occur during a hemodialysis session and are not related to the degree of ultrafiltration
Prujim M., Teta D., Rotaru C., Waeber B., Burnier M., Feihl F. – Lausanne
P 48 Assessment of subjective and hemodynamic tolerance of different high- and low-flux dialysis membranes in patients undergoing chronic intermittent hemodialysis : a randomized controlled trial
Bianchi G.1, Salvadé V.1, Lucchini B.1, Schätti-Stählin S.1, Salvadé I.1, Burnier M.2, Gabutti L.1
1 Locarno, 2 Lausanne
42 | Final program SGN-SSN Interlaken | 43
Poster presentationsPoster presentations
P 63 Flow-mediated regulation of sodium transport in the collecting duct Ernandez T., Chassot A., Avila Y., Martin P.-Y, Féraille E. – Geneva
P 64 Impact of uninephrectomy on body L-arginine homeostasis and blood pressure control in mice
Pillai S.M., Verrey F. – Zurich
P 65 Comprehensive analysis of hypoxia-regulated gene transcripts in chronic kidney disease and renal cells
Shved N., Lindenmeyer MT., Brandt S., Hoogewijs D., Wenger R., Kretzler M., Wild P., Cohen CD. – Zurich, Michigan/US
P 66 Very early exposure of fetal kidneys to chronic hypoxia triggers upregulation of genes involved in glucose and fatty acid metabolism
Rodriguez S.1, Janot M.2, Rudloff S.1, Huyn-Do U.1
1 Berne, 2 Nancy/FR
P 67 Proteomic study of FFPE IgA nephropathy biopsy tissue by using OSDD and SWATH-MS methods
Xu B.1, 2, Zhang Y.2, Liu Y.1, Rosenberger G.1, Wild P.J.1, Kistler A.1, Yamamoto T.2, Aebersold R.1
1 Zurich, 2 Niigata/JP
P 68 Recurrent transient renal Fanconi syndrome : adverse effect of the artificial sweetener cyclamate
Kürth J.1, Prader S.2, Rentsch KM.1, Devuyst O.1, Neuhaus T.J.2
1 Zurich, 2 Lucerne
P 69 Oxygenation of the renal cortex : computational modeling and anatomical observations
Olgac U., Kurcuoglu V. – Zurich
P 70 Role of sodium-dependent phosphate transport protein 2C (NaPi2c) in osteoclasts
Albano G.1, Moor M.B.2, Hernando N.3, Hofstetter W.1, Biber J.3, Bonny O.2, Fuster D.G.1
1 Berne, 2 Lausanne, 3 Zurich
Renal pathology
P 56 TREX1 mutations – one of the genetic causes for renal vascular diseases in younger patients
Menter T.1, Winkler D.T.1, Isimbaldi G.2, Hopfer H.1, Mihatsch M.J.1
1 Basel, 2 Monza/IT
P 57 Fibrosis of solid organs : towards a common classifier across species Marti H.-P.1, Fuscoe J.C.2, Kwekel J. C.2, Scherer A.3
1 Bergen/NO, 2 Jefferson/US, 3 Kontiolahti/FI
P 58 The spectrum of renal pathology findings in armenian and swiss children : differences and similarities – comparison of two decades
Laube G.F.1, Sarkissian A.2, Nazaryan H.2, Sparta G.1, Sanamyan A.2, Babloyan A.2, Leumann E.1, Gaspert A.1
1 Zurich, 2 Yerevan/AM
NCCR kidney.ch
P59 Uninephrectomy of HFD-induced obese mice greatly accelerates proteinuria, fibrosis and changes in gene expression
Gai Z., Kullak-Ublick G.A. – Zurich
P 60 Coupling between transcellular Na+ transport and paracellular permeability in collecting duct cells
Wang Y.-B., Ernandez T., Féraille E. – Geneva
P 61 Furosemide stimulation of parathyroid hormone in humans : role of the calcium-sensing receptor and renin-angiotensin system
Forni Ogna V., Muller M.-E., Maillard M., Zweiacker C., Wuerzner G., Bonny O., Burnier M. – Lausanne
P 62 V-ATPase B1 subunit polymorphism p.E161K affects urinary acidification in vivo
Dhayat N., Pasch A., Fuster D. – Berne
44 | Final program SGN-SSN Interlaken | 45
Firm Booth
Abbvie 10Amgen 8Astellas 15Bracco 29Baxter – Gambro Renal 1B.Braun 2BMS 28Dialmed 30Dr. G. Bichsel 27Euromed 18Nephro-Medical Schweiz 31Nephr. Pflege 26Fresenius 7Baxter – Gambro Renal 16gd medical 24Ifw 25Lab. Dr. Bichsel 21MSD 6Novartis 9Opo Pharma 14Pfizer 13Pro Farma 17Roche 12Sandoz 19Sanofi 11Servier 23Shire 3The Binding Site 22Theramed 5Vifor 20aVifor 20
PlanExhibitors
46 | Final program SGN-SSN Interlaken | 47
Sponsored congress itemsPfizer AG, ZurichBadges and Lanyards
Sandoz Pharmaceuticals AG, RotkreuzPoster prize awards
Sanofi-aventis (Schweiz) AG, VernierCongress bags
Vifor Pharma, Villars-sur-GlâneWelcome aperitif, signage onsite
AdvertisementAbbvie AG
Alexion Pharma International
Amgen Switzerland AG
Baxter – Gambro Renal
Fresenius Medical Care (Schweiz) AG
Novartis Pharma Schweiz AG
Pro Farma AG
Roche Pharma (Schweiz) AG
Vifor Pharma
KindthankstothemunicipalityofInterlakenforitsfinancialsupportandwelcome
Abbvie AG, BaarParallel satellite lunch symposiumFriday, December 6, 201312.00-12.45 / Room B
Amgen Switzerland AG, ZugSatellite symposiumFriday, December 6, 201309.30-10.15 / Room A
Baxter – Gambro Renal, VolketswilParallel satellite lunch symposiumFriday, December 6, 201312.00-12.45 / Room A
Novartis Pharma Schweiz AG, RotkreuzSatellite lunch symposiumThursday, December 5, 201312.00-12.45 / Room A
Vifor Pharma, Villars-sur-GlâneSatellite symposiumThursday, December 5, 201309.30-10.15 / Room A
Sponsored symposia in alphabetical order
48 | Final program SGN-SSN Interlaken | 49
City map of Interlaken
Aare
Wildpark
Bleikiwald Äbnit
ZunTschingel
Burgseeli
Brie
nzstrasse
Freiestrasse
Kammistrasse
Lanzenen-Promenade
Dam
mw
eg
Ha u
p tst
r as s
e Säumerweg Eyenweg
EyenwegEyenweg
Eyen
-
Felseneggweg
Hube
l- str.
h-
pt t s
-n e
Eggelti str.
Walmweg
Stapf ackerwe g
a ss
rah
rAareweg
Goldswilhu-belweg
Burgweg
Hon drichweg
Strandbadweg
Lochstrasse
P
P
P
PP
P
P
P
P
P
Bagger-seeli
Mattli
Wanna
ei
Gei
ssga
sse
Lüts
chin
enst
rass
e
r n s r se
Nor
dstr a
s se
Interlaken-strasse
Erlen
-weg
Schw
eliwe
Fried
heim
O
FriedheimEywegNiesenwegRenggli-weg
Gartenstras se
Chirs-dorri-weg
Im
Neue
nstr.
Wyd
iw
eg
Blumenstr.
M enstrasse
Hauptstr.
Alpe
nstra
sse K
Alte
r Kirc
hwegRo
ssac
her-
wegLisch-
maadw
eg
Lischm
aadweg
++
Aare
Feld
Rosslauf
öhe- Matte
Hohbühl
Herti
Ägerti
Senggi
Wildpark
Bleikiwald
Ob. Moos
Ändermoos
Mittl. Moos
Interlaker Ey
Flugplatz
Uf der Acheri
Im Zun
Oberi Erle
WilderswilerMoos
Tschingel
raro
en d
erarr
e
Gros
seAa
re
Spielmatte
bere G
Harder-P
romenade
Mar tg
ass e
Blumen- str.
ostga
sse
Har
detra
sse
m na
arst
rass
e
Klosterstrasse
Li ena
portw
eg
ber-Allee
c l ss t sse
Strandbadstrasse
age-
brüc
ke
Brie
nzstrasse
estrasse
waerenw
e
rrw
eg
Reng
g lwre
stra
sse
men
rass
e
llmen
trass
e
i te a e s r ss
ten
aben
- str s e
ac we
re s rasseühlstrasse
Untere Bönigstrasse
Kammistrasse
Lanzenen-Promenade
Dam
mw
eg
Send
listra
sse
Gei
ssga
sse
U tere Bön
n
igstr.
Lanzenen
Hohlengässli
au tstrasse
ren
we g
srg
s
Lärch
enweg
nterdorfstrasselte Unter rf sse
a
e
Oelestrasse
Kess
lerg
asse
Hau p
tstr a
sse
Me rgasse
aum a ns .
Brunngasse
Dorfs
t r .
Rü ss
fer s
eertenstrasse
ircäs
sli
c re
a n s
ue zac erwe
erg
ss
Gst
rass
e
Herti
gäss
li
eni
ässl
osenwe
rw
enrber
trasse
ssli
ei s
Herz
Scssli
Kupfergasse
Rütistrasse
e es rasse
Obere Bönigstrasse
Aenderbergstr.üt
sch in
enstr
asse
aupt
stra
s s
Säumerweg Eyenweg
EyenwegEyenweg
Eyen
-Schild-matta
Felseneggweg
Hube
l- str.
wa ldgasse
Hobacher-
gasse
Hauptstrasse
Dorfgasse
Bromat-tenweg
Plattenweg
Salz-
Eggelti str.
Walmweg
Stapf ackerwe g
Tal strasse
Talstrasse
TalstrasseGüntschenacherwegAarewegAareweg
Goldswilhu-belweg
Büelweg
Wenglacherweg Ru
gens
tr.
brüc
ke
P
P
P
we
g
P
P
P
P
P
Allmi
P
P
P
PP
P
P
P
P
P
i tori stras
hubelweg
P
asse
Aegertiweg
Mittengraben-
Interlaken Ost
H
Und. Moos
Underi Erle
Sendli
Gsteigs
trass
e
Matten
Gsteigs
trasse
++
Thunersee
Neuhaus
Luegibrüggli
Eywald
Lehn OberesStadtfeld
UnteresStadtfeld
Rossmeder
N a t u r r e s e r v a t
Golfplatz Moos
Weissenau
LütscheraSchiff-KanalAare
Widihof
Leimener
Lehnzun
Eichzun
GrütLombach
UnterseenBreite
Rychegarte
Im Under
GrosseRuge
Heimwehfluh
Tschingeley
Mad
Kana
l
Aare
Aare
Interlaken West
Herreney
Müliholz
Brandwald
Lombachzun
LuziwichelChammflue
Schibeflue
Im Brand
WagnerenSchlucht
Chlyne Ruge
Waldegg
Höhe- Matte
Goldey
VorderHarder
Hardermandli
Hohbühl
Herti
Juhei
Öli
Wildpark
Brüggwald
Bleikiwald
ilgerweg
Seestrasse
Lombach-Promenade
Eyweg
B
Weissenaustra
sse
Widigässli
Widigässli
Wyd
engä
ssli
Seestrasse
Mittlere Strasse
Lehnweg
Bockstorweg
Lombachzaunweg
Guet
ehus
estr.
Stad
tfeld
str. StadtfeldstrasseSteindlerstrasse
Vorholzstrasse
Tschin
geley
- strasse
Spitalweg
Gur
bens
trasse
Weissenaustra
sse
Helvetiastrasse
Seestrasse
Breitengässli
E ig erstrasse
Mittlere Strasse Schulhausstr.
Schulhausstrasse
See strasse
Seidenfadenstrasse
Am Lauener
Hohmüedig
Gumm
enstr.
Mühleholzstrasse
Mühleholzstrasse
Beatenbergstrass e
Brand-Promenade
Brand-PromenadeBeatenbergstrasse
Scheidgasse
Scheidgasse
GartenstrasseHint. Scheidg.
Dorfmatten-str.
Bohne
renstr.
Ober-dorf
Unterdorf
Freihofstrasse
Auf de
m Grab
enObe
re Gas
se
Unt. G
asse
Mühle-gässli
Hauptstr.
Haber-
darreHab
-ke
rn-
gäss
li
Kreuz-gasse
Klein
e Aar
e
Gros
se A
are
Bahnhofstrasse
Aarestr
asse
Spielhölzli
Baumgartenstrasse
Spielmatte
Obere Goldey
Untere Goldey
Harder-P
romenade
Brand-Promenade
Goldey-Promenade
Därligenstrasse
n
Tschi
geley
stras
se
Kanalpromenad
e
iFabr kst
rasse
Fabr
ikstra
sse
Ruge
npar
kstra
sse
Fried-
Fried- weg
Waldeggstrasse
Rugenaustrasse
Rothornstr.
Bernastrasse
General-Guisan-Strasse
Bahn
hofp
latz
Bahnhofstrasse
Aare
ckstr
asse
Niesenstrasse
Florastrasse
Aarmühlestrasse
Post-kreisel
Marktgasse
Neugasse
Post
gass
e
Blumen- str.
Postg
asse
Har
ders
trass
e
Höheweg Höhe-Promenade
Jungfraustr.
Unions-
gasse
Centralstr .
Jungfraustrasse
Rose
nstra
sse
Alpenstrasse
Suleggstr. Wal
degg
stras
se
Pfarrweg
Park
stra
sse
Alpenstrasse
Klosterstr
asseLindenallee
Spor
tweg
Peter-Ober-Allee
Schlossstrasse
Strandbadstrasse
Reckweg
Beau
rivag
e-br
ücke
Brie
nzstrasse
Freiestrasse Schwalmerenw
eg
Burg
erw
eg
Reng
g li -
weg
Frei
estra
sse
Allm
ends
trass
e
Allm
ends
trass
e
Mittengrabenstrasse
Mitt
engr
aben
- strasse
Spühlibachw.
Obere Bönigstr.Bühlstrasse
Abend- berg-strasse
Heimwehfluh-strasse
Heimweh
fluhs
trass
e
Wagner enstrasse
Hohlengässli
Rugenstr
asse
Ring
weg
Ringweg
Wychelstrasse
Hubelweg
Jun g
frau-
blic
k al le
e Hauptstr. Birk
enw
e g
Klos
terg
ässl
i
Lärch
enweg
UnterdorfstrasseAlte UnterdorfasseHobachergässli
Oelestrasse
Kess
lerg
asse
Reginaweg
Beundenweg
Tellweg
Hau p
tst r a
sse
Metzgergasse
Baumgartenstr.
Brunngasse
Dorfs
t r.
Rütigässli
Kupfergasse
Aegertenstrasse
Kirc
hgäs
sli
Eyach re i
MattenstrasseFliederweg
rK ue zackerweg
Herti
gäss
li
Feld
gäss
li HortensienwegDahlienweg
Nelkenweg
Gsteigst r.
Herti
gäss
li
Senggigässli
Rosenweg
Flur
weg
Aenderbergstrasse
Juheigässli
Juheigässli
Herziggässli
Schulgässli
Kupfergasse
Rütistrasse
Wenglacherweg Ru
gens
tr.
nach Bern/Spiez/Thun
Därligenstrasse
Breite
Wel
len a
c he r
Kirch-
gasse
Unte
r den
Häus
ern
Scha
al-br
ücke
P
P
P
P
P
P
P
P
P
P
P
P
P
P
PP
P
P
P
P
P
P
PP
P
PP
P
P Viktori astrass e
P P
Bühls
trass
e
Aegertiweg
Lischzun
g
att
Guggerschopf
Bödeliblick
Lustbühl
e
Felsenegg
Tanzboden
Hohrugen
Möösli
In den Rüglenen
Rugen
Lindi
Plöschi
Blasiegg
Sidefade
Gumme
Sackgut
Ried-graben
Goldswil Buech
nach Thun/Bern
938602
590
586
•
•
•
561•
•
596•
714•589•
577
565
565
•
•
•
559•
558•
558•
559
562
561
•
•
•
564
570
570
564
563
562
647
649
665579
591
598721
593
576
604
575
579
575
571
571
569
568
567
567
626
567 567
568
588
590
787
565 565
598
563
567
572
777
682
•
•
•
•
•
•
•
•
•
••
•
•
•
•
•
•
569•
•
•
•
•
•
•
••
•
•
•
•
•
•
•
•
•
•
•
•
•
566•
••
569•
•
•
574
576
•579
566•
•
Golfklub
Manor-Farm
Alpenblick Deltalandeplatz
Lombachsteg
Hobby
Lazy Rancho
Sportplatz
Schulhäuser
Kindergarten
Jungfrau
Regionalspital
Schi
esss
tand
Werkhof
Congress Centre Kursaal/ Casino
Aula
Schulhaus
Schloss Interlaken
Turnhalle
Engl. GartenDenkmal
Sackgut (TCS)
Station
Tierheim
Fussballplätze
Kehricht-Umladestation
Sportplätze
Berufsschul-zentrum
BZIKinder-gartenSchulhäuser
Gymnasium
Tell-Freilichtspiele
Pfadfinderheim
ReservoirModelleisenbahn
Rodelbahn
Station
BKW-Bödeli
RugenbräuJungfraublick
E.W.
Trinkhalle
Fototurm
Heimweh
fluh-
Bahn
Schulhäuser
Kirchgem.-HausGemeindehaus
Sportplatz
SchulhausGemeindehaus
Kläranlage ARA
Ruine Weissenau
Station
Harderbahn
-resuahneknarFnietS
Brünigbahn SBB
Berner Oberland-Bahn
P
P
P
Schiffstation
Schiffstation
P
103
21 Brienzer- see
4038
1
2
39
3
4 5
7 8
44
Stampach
Unders Ried
Ofni
Egg SchwandeUnspunnen
Büel
Greiche
Tschingel-matte
Roteflue
Fliesau
Bir Sagi
Wilderswil
Ägertzun
Plöschi
Feld HertiÄgerti
BimGrüt
Rosshag
Gsteig
LenggFuchsegg
Fuchseggwald
Gsteigwiler
Chilchegg
Änderberg
Undre Zun
Schönegg
Schwendi
Breitlauenen
Schürläger
Dunkle Bode
Allmi
Uf der Acheri
Mattewald
Hohlengässli
Herti
gäss
li
Aenderbergstrasse Gsteigs
trass
e
Aenderbergstrasse
Gubiweg
Saxetenstrasse
Obere H
a lte
Haltenweg
Halte nweg Grench
enweg
Grenc henstrasse
Staatsstrasse
Saxetenstrasse
MühlenenstrasseKreuzgasse
Hub
elweg
Bühlgäs sliSte
ini w
egTa
lweg
Kupfer-gasse
Lehngasse
Bären-platz
Oberdorfstrasse
Oberdo rfstrasse
Plattenweg
Ruge
nstra
s se
UnspunnenstrasseW
englacherweg
Ruge
nstra
sse
Obere Lenge Streich
Mat
tenw
eg
Feldgäs sli
Plöschiweg
Stockacherweg
Scheurenweg
Scheurenweg
Gärbigässli
Sydachstrasse
Sydach-weg
Kirchgasse Kirchgasse
Fuhr enwä g li
Schulgässli
Mühlenenfeldw
eg
Dickiweg
Dickiweg
Obereigasse
Obereigasse
Wyd
i-g ä
ssli
Wydistr.
Wydistr.Hinterwydi
Alte Staa
tsstr.
Hauptstrasse
Allmendstr.
BönigstrasseMitte
lwegAlte Staatsstr.
Bönigstr
asse
Haupts
tr.
Aege
rt-
Kreuzimaadweg
Aegertzaun-weg
Jungfrau-weg
zaun
stra
sse Ro
ssha
agweg
Kirchweg
Gs teigstr ass e
Lüts
chine
Saxetbach-weg Obe
rei-weg
Unt
er d
er F
u hr e
Unt
er-
dorf-
weg
Dam
mw
eg
Aegertiweg
Stockacker
Rosslauf
Oberdorf DorfmatteSchafmatte
Dickimatte
Oberey
Mühlenenfeld
→ n
ach
Inte
rlake
n un
d A8
→ G
rindelwald, Lauterbrunnen, G
ündlischwand
nach Saxeten ←
AVARI – Fernheizwerk/District heating plant
Parkpla
tz/
Parking
Schynig
e Platt
e
Kirche Gsteig/ Gsteig Church
→ nach Brienz/Luzern← nach Spiez/Thun/Bern
→
nach Bönigen/Iseltwald
Ruine Rotenfluh
Camping Oberei
→
Schynige Platte BahnSchule/School
Schule/School
Tennispark Jungfrau/ Sports Center
P
DorfmuseumVillage Museum
GedenkstätteMemorial
ü
3Kinderspielplatz
Playground for childrenSchmiedmatte
2Ruine Unspunnen
GemeindeverwaltungLocal Council Office
GemeindeverwaltungLocal Council Office
SchuleSchool
DorfladenGrocery Storel
Christliches Internat
Gsteigwiler
5
Berner-
Oberla
nd-B
ahn
SPB
Oberland ShoppingR
Skilift Bockler
Alpin
Center
/
Sk
ischu
le/Sk
i scho
ol
2
Minifit Parcours (Start)
Rega Helikopter Basis
→BOHAG Helikopter Basis
1
16
18
0 500 m 1000 m
N
© media swiss ag
Rugenbräu593•
RugenE.W. 579•
L
Musterplatz
105
105
n
ach
Sa
xete
n
Bus
tran
sfer
v
orha
nden
2
1
3
4
5
6
7
8
9
10
a b c d e f g h i j k l
2
1
3
4
5
6
7
8
F3 Aarburg F5 Alp Horn H6 Alpina H4 Arnolds Bed & Breakfast I4 Artos F4 Bahnhof G4 Bären I3 Lindner Grand-Hotel Beau-Rivage F3 Beau-Site G3 Bellevue F4 Bernerhof G5 Beyeler/Heidi’s Hostel G4 Blume I3 Carlton-Europe F4 Central-Continental F3 Chalet-Swiss G4 City Hotel Oberland F5 Crystal F5 De la Paix G5 Derby I3 Du Lac H3 Du Nord G3 Goldey C3 Golf, Landhotel H3 Hapimag Belvedere G3 Harder-Minerva H5 Hirschen, Gasthof
57 17969889 4 5277
345446186478 30 35 5191 61
9080 7458407266 91
hotels interlaken
F10 Alpenblick G10 Alpenrose F10 Bären F10 Berghof Amaranth F11 Chalet-Hotel-Heimat H10 Christina F9 Credo Schloss Unspunnen H10 Gasthof Hirschen
1 6 2 3 8 901
11
hotels wilderswil
G3 Alp Lodge H4 Backpackers Villa Sonnenhof H5 Balmer’s Herberge H6 Funny Farm G4 Happy Inn Lodge
54 739295
hostels interlaken
A2 Manor Farm A3 Alpenblick C3 Hobby C2 Lazy Rancho
1 2 3 4
camping interlaken
G11 Oberei 1camping wilderswil
H3 Interlaken F5 Katy’s Lodge G4 Krebs F5 Lötschberg B1 Luegibrüggli F4 Merkur G4 Metropole A3 Neuhaus Golf-/Strandhotel I5 Orion Appartementhaus H6 Park Mattenhof F3 Post-Hardermannli C3 Residence Golf F3 Rössli H3 Royal-St.Georges F5 Rugenpark G4 Savoy H6 Sonne (Matten) G4 Splendid G4 Stella F4 Sunny Days Bed & Breakfast G5 Swiss Inn Hotel & Appartements H6 Tell G4 Toscana F4 Touriste F7 Unspunnen, Gasthof G3 Victoria-Jungfrau F7 Waldhotel Unspunnen G4 Weisses Kreuz
38
75 124713 44 268 39 97 95 42
4376 20 8894
87 32149363 11 2369 2461
65
G10 Jungfrau F10 Kreuz G11 Motel Luna Park Resort F10 Schönbühl J12 Berghotel Schynige Platte H11 Gasthaus Steinbock F10 Villa Unspunnen Alpenrose Saxeten
4 12 1314181651
17
G5 Heidi’s Hostel G3 Hostel Falken J3 Koreahof GmbH Hostel J3 River Lodge H8 Balmers Tent Village 6 8
18
81
85
56
D2 Jungfrau J3 Sackgut (TCS) H8 Jungfraublick
5 6 7
I2 Alpenwildpark/Parc zoologique alpin/Alpine wildlife park Aussichtspunkt/Point de vue/Point of view Bahnhof/Gare/Railway station Bancomat, Change/Distribanque/Money exchange, Atm mach G4 Bibliothek/Bibliothèque/Library F4 Billard H3 Boccia/Pétanque/Bowls H2 Bödelibad/Piscine/Pool G4 Bödelibahn/Tour de ville/Sightseeing G4 Bödelitram/Tour de ville/Sightseeing K5, G4 Bowling Interlaken/Kegeln H3 Congress Centre Kursaal/Casino B3 Deltalandeplatz/Aire d’atterr. p. Deltas/Hang-glider landing area H6 Eissportzentrum/Curling/Patinoire/Artificial ice-rink A3, B8, D6,F6 Feuerstelle/Place de grill/Barbecue facilities A4, H2, L2 Freibad/Piscine en plein air/Open-air pool K3 Fussballplatz/Terrain de football/Football pitch F5 Fundbüro/Objets trouvés/Lost & Found B4 Golf I3 Japanischer Garten/Jardin japonais/Japanese Garden F3, F6, G5,H2, 4, I7, J3 Kinderspielplatz/Aire de jeux p. enfants/Childr. playgr. G4 Kino Rex, Piccolo/Cinéma/Cinema F3, H4 Kirche/Eglise/Church G4 Kletterhalle K44/Halle d’escalade/Climbing Hall F4, G4 Kutschen/Carrosses/Carriages G3 Ludothek/Ludothèque/Toy library A2, G2 Minigolf/Golf miniature/Mini-golf Naturgarten/Jardin/Nature garden Parkplatz/Parking/Car park Post/Poste/Post office F3, C4 Reitstall/Centre d’équitation/Riding stables C6,F8, K2 Ruine/Ruine/Ruins A3, F4, J3 Schiffstation/Station d’embarquement/Boat landing Tourist Information H4 Schloss/Château/Castle F7 Seilpark/Parc d’aventure/Rope park A3 Segeln/Voile/Sailing K6 Skate Park Skilift/Remonte-pente G4 Spielsalon/Salon de jeu/Amusement arcade E4 Spital/Hôpital/Hospital A3 Surfen/Planche à voile/Windsurfing G6 Tell-Freilichtspiel/Théâtre en plein air Tell/Tell open-air theatre G3, H4,8 Tennis/Squash J3 Tierpension/Pension pour animaux/Kennels F3 Touristikmuseum/Musée touristique/Museum of Tourism D1 Vita Parcours/Parcours Vita/«Vita» outdoor training trail F3, G3 Wäscherei/Laverie/Laundry H4 Zinnfiguren-Ausstellung/Exposition de figurines d’étain/Tin Figure-Exhibition
P
Interlaken – Beatenberg Interlaken – Ringgenberg Interlaken – Bönigen – Iseltwald Ortsbus Interlaken Interlaken – Wilderswil – Gsteigwiler Interlaken – Habkern STI Interlaken – Thun
101
102
103
104
105
106
21
Saxeten
SchuleSchool
nach
Wild
ersw
il ←
Clubhütte Bällenblick TV Matten
Skihütte Buechmatte SaxetenSkiklub Wilderswil
Nessleren Schlittelweg ↓
Skilift Pintli
GemeindeverwaltungLocal Council Office
Restaurant Pintli
17
P
11 11
10
9
12 12
13 13
14 14
Interlaken
GALA DINNER
19.30 Aperitif20.00 Dinner
The magnificent rooms of the Casino Kursaal Interlaken date from the 19th century and provide a perfect setting for the Gala Dinner of the Swiss Society of Nephrology.
You will enjoy this unique atmosphere, combined with first-class service and excellent cuisine.
We await your reservation with pleasure when registering online on www.meeting-com.ch. Additional tickets will be available at the registration desk on a first come first served basis.
Pre-reservation is highly recommended. Price : CHF 70.00/ticket.
Congress Centre Kursaal Interlaken – Strandbadstrasse 44 – 3800 Interlaken
Thursday, December 5 Ballsaal / Room B
50 | Final program SGN-SSN Interlaken | 51
Kind thanks to all our sponsors Kind thanks to all our sponsors
MUNICIPALITYINTERLAKEN
52 | Final program SGN-SSN Interlaken | 53
Notes
We would like to invite you to the :
46th Annual Meeting of the Swiss Society of Nephrology (SGN-SSN)On December 3-5, 2014 – Congress Centre Kursaal Interlaken
Please save the dates of December 3-5, 2014 !We already look forward to welcoming you in Interlaken next year !
www.swissnephrology.ch
Schweizerische Gesellschaft für NephrologieSociété Suisse de NéphrologieSocietà Svizzera di Nefrologia
Save the date : SGN-SSN congress 2014
54 | Final program
Notes
Die Kunst der shpt-Kontrolle
Durch die gleichzeitige Senkung aller drei bio- chemischen Schlüsselparameter (PTH, Kalzium und Phosphat),1,2 verbessert Mimpara® die Kontrolle des sekundären Hyperparathyreoidismus (sHPT).3–5
MN
-CH
E-A
MG
-283
-201
3- S
epte
mb
er-PKurzfachinformation: Mimpara® (Cinacalcet):
Calcimimetikum. Es senkt direkt die Parat-hormonspiegel indem es die Empfindlichkeit des Calciumsensitiven-Rezeptors auf extrazelluläres Calcium erhöht. Die Reduktion der Parathormon- spiegel ist mit einer gleichzeitigen Abnahme der Serumcalciumspiegel verbunden. Indikatio- nen: Zur Behandlung von sekundärem Hyperpa-rathyreoidismus bei dialysepflichtigen Patien- ten mit chronischer Nierenerkrankung. Zur Be- handlung der Hyperkalzämie bei Patienten mit Nebenschilddrüsenkarzinom und bei Patienten mit primärem Hyperparathyreoidismus, bei denen die Entfernung der Nebenschilddrüse keine Behandlungsmöglichkeit darstellt. Dosie- rung/Anwendung: Mimpara® wird oral ge-geben. PHPT: Empfohlene Anfangsdosis für Er- wachsene ist 30 mg zweimal täglich. Die Dosis von Mimpara® kann ausgehend von zweimal täglich 30 mg, alle 2 – 4 Wochen auf 60 mg zweimal täglich, 90 mg zweimal täglich, bis zu 90 mg 3 – 4 x täglich erhöht werden, abhängig von der Normalisierung der Serumcalcium-spiegel. Der Serumcalciumspiegel sollte inner-halb der ersten Woche nach Beginn der Therapie oder Dosisanpassung von Mimpara® gemessen werden. Nachdem die Erhaltungsdosis fest-gelegt wurde, sollte der Serumcalciumspiegel alle 2 – 3 Monate gemessen werden. SHPT: Empfohlene Anfangsdosis für Erwachsene ist 30 mg einmal täglich. Alle 2 – 4 Wochen auf-
titrieren, bis zur Erreichung des iPTH Zielwert von 150 – 300 pg/ml. Serumcalciumspiegel während der Titrationsphase häufig, in der Erhaltungs- phase monatlich kontrollieren. Parathormon 1 – 4 Wochen nach Therapiebeginn oder Dosisanpas- sung messen, in der Erhaltungsphase alle 1 – 3 Monate kontrollieren. Kontraindikationen: Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe gemäss Zusammen- setzung. Warnhinweise und Vorsichtsmass-nahmen: Anfälle: Der Schwellenwert für An- fälle ist bei einer signifikanten Reduktion der Serumcalciumspiegel herabgesetzt. Serumcal-cium: Da Cinacalcet die Serumcalciumspiegel erniedrigt, sollten Patienten auf Hypokalzämie-symptome überwacht werden. Bei mit Mimpara® behandelten Patienten, einschliesslich pädia-trischen Patienten, wurde im Zusammenhang mit Hypokalzämie von lebensbedrohlichen Ereignissen und Todesfällen berichtet. Falls die PTH-Spiegel bei mit Mimpara® behandelten Patienten tiefer als die unteren empfohlenen Zielwerte sinken, sollten die Dosierung der Vitamin-D-Sterole oder von Mimpara® reduziert bzw. die Behandlung abgebrochen werden. Interaktionen: Ketoconazol: Cinacalcet wird teilweise durch das Enzym CYP3A4 metaboli-siert. Die gleichzeitige Verabreichung von Ketoconazol resultiert in einer ungefähr 2fachen Erhöhung der Cinacalcet-Spiegel. Arzneistoffe, die durch CYP2D6 metabolisiert werden: Es
konnten keine Interaktionen beobachtet wer- den, wenn Mimpara® gleichzeitig mit folgenden Arzneimitteln zusammen gegeben wurde: Se- velamer, Calciumcarbonat, Warfarin und Panto- prazol. Unerwünschte Wirkungen: Stoffwech-sel und Ernährungsstörungen: Häufig: Anorexie, Hypokalzämien. Nervensystem: Häufig: Schwin-del, Parästhesien. Gastrointestinale Störungen: Sehr häufig: Übelkeit, Erbrechen. Haut: Häufig: Rash, Muskelskelettsystem: Häufig: Myalgie. Reaktionen an der Applikationsstelle: Häufig: Astenie. Untersuchungen: Häufig: Verringerte Testosteronwerte. Packungen: Filmtabletten mit 30, 60 und 90 mg Mimpara® in Blisterpa- ckungen à 28 Stück. Ausführliche Angaben ent-nehmen Sie bitte der Fachinformation unter www.swissmedicinfo.ch. Zulassungsinhabe-rin: Amgen Switzerland AG, Zug. Verkaufs- kategorie B. MN-CHE-AMG-287-2013- September-P
Referenzen: 1. Messa P et al. Clin J Am Soc Nephrol 2008; 3(1): 36–45. 2. Frazão JM et al. Clin Nephrol 2011; 76(3): 233–243. 3. Ureña-Torres PA et al. Nephrol Dial Transplant 2013; 28(1): 146–152. 4. The EVOLVE trial investigators. N Engl J Med 2012; 367(26): 2482–2494. 5. Block G et al. Kidney Int. 2010; 78: 578–589.
AMGEN Switzerland AG, Dammstrasse 216301 Zug, www.amgen.ch
Mimpara_Inserat_A5.indd 1 25.09.13 14:10
Eisentherapie. Befreiend einfach.
Einfach. Schnell. Wirksam.
Bewährt durch langjährige Erfahrung
bei Patienten mit Eisenmangel1,2,3,4
YOUR IRON PARTNER SINCE 1991
www.ferinject.ch www.iron.medline.ch
Ferinject®. Z: Eisencarboxymaltose. I: Eisenmangel, wenn orale Eisentherapie ungenügend wirksam, unwirksam oder nicht durchführbar ist. D: Die kumulative Gesamtdosis von Ferinject® muss individuell berechnet werden. Ferinject® kann als intravenöse Infusion (verdünnt in 0,9% NaCl) in wöchentlichen Einzeldosen von bis zu 15 mg/kg, maximal 1000 mg, bis zum Erreichen der berechneten kumulativen Gesamtdosis verabreicht werden. Als i. v. Bolusinjektion kann Ferinject® (unverdünnt) in Dosen von bis zu 200 mg Eisen pro Tag verabreicht werden, jedoch nicht mehr als 3×/Woche. KI: Überempfindlichkeit gegenüber Wirkstoff oder Hilfsstoffen, Anämie ohne gesicherten Eisenmangel, Eisenüber-ladung, erstes Schwangerschaftstrimester. VM: Vorrichtungen zur Behandlung einer anaphylaktischen Reaktion sollten verfügbar sein. Paravenöse Injektion kann eine braune Verfärbung und Reizung der Haut verursachen und ist deshalb zu vermeiden. Bei akuter oder chronischer Infektion nur mit Vorsicht anwenden. Natriumgehalt von bis zu 11 mg/ml berücksichtigen. UW: Hypersensitivität, Kopfschmerzen, Schwindel, Parästhesien, Tachykardie, Hypotonie, Erröten, gastrointestinale Beschwerden, Störung des Geschmacks-empfindens, Hautausschlag, Pruritus, Urticaria, Myalgie, Rückenschmerzen, Arthralgie, Hämaturie, Reaktionen an der Injektionsstelle, Phlebitis, Fieber, Müdigkeit, Schmerzen im Brustkorb, Muskelsteifigkeit, Unwohlsein, peripheres Ödem, Schüttelfrost, transiente Serumphosphatsenkung, erhöhte Alanin-Aminotransferase, Aspartat-Aminotransferase, Gamma-Glutamyltransferase, Laktatdehydrogenase und alkalische Phosphatase. IA: Bei der gleichzeitigen Verabreichung von oralen Eisenpräparaten ist deren Absorption reduziert. P: 5 Stechampullen zu 100 mg (2 ml) oder 500 mg (10 ml) und 1 Stechampulle zu 500 mg (10 ml). Liste B. Detaillierte Informationen: Arzneimittelkompendium der Schweiz oder www.documed.ch. Zulassungsinhaberin: Vifor (International) AG, CH-9001 St. Gallen; Vertrieb: Vifor AG, CH-1752 Villars-sur-Glâne.
Referenzen: 1. Wick M et al. Eisenstoffwechsel, Anaemien. Diagnostik und Therapie 2002; Springer-Verlag Wien New York: ISBN3-211-83802-3 2. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101(1):67–73 3. Anker SD, Comin CJ, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361(25):2436–2448 4. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant (2011) 26: 1599–1607.
Vif_Ferinj_A5_Ref_hoch_dt_RZ.indd 1 28.01.13 15:12